# Clinical Trial for GNX80 in Intermittent Claudication

Study · id `cardio:ct-nct05400395` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05400395](<https://clinicaltrials.gov/study/NCT05400395>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05400395

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT05400395. Randomized; quadruple masking; primary purpose treatment. Start 2022-09-05 (actual); primary completion 2024-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT05400395, source copy `cardio:ctgov-nct05400395-2022-10-27`, retrieved 2026-10-31)
- Started: 2022-09-05 (actual) (ClinicalTrials.gov record NCT05400395, source copy `cardio:ctgov-nct05400395-2022-10-27`, retrieved 2026-10-31)
- Primary completion: 2024-03 (anticipated) (ClinicalTrials.gov record NCT05400395, source copy `cardio:ctgov-nct05400395-2022-10-27`, retrieved 2026-10-31)
- Completion: 2024-08 (anticipated) (ClinicalTrials.gov record NCT05400395, source copy `cardio:ctgov-nct05400395-2022-10-27`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT05400395, source copy `cardio:ctgov-nct05400395-2022-10-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05400395-2022-10-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: Clinical Trial for GNX80 in Intermittent Claudication
- Condition: Intermittent Claudication
- Intervention (Drug): GNX80
- Intervention (Drug): Placebo
- Lead sponsor: SK Chemicals Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: SK Chemicals Co., Ltd. (`cardio:org-sk-chemicals-co-ltd`)

## Provenance

Content hash: 5c964a63b890b9cc7e003d4f4c9f2d346ea5ff7008fd584d9afe974bc1684563
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
